The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: Results of the phase 2 NAVIGATION study.
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Naomi Kiyota
Honoraria - Bayer; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Bayer; GlaxoSmithKline; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Kirin Pharmaceuticals (Inst); Ono Pharmaceutical (Inst)
 
Ken Saijo
Honoraria - Novartis
Research Funding - Takeda Science Foundation
 
Yoshitaka Honma
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; GenMine Labs; Kirin Pharmaceuticals; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; GenMine Labs; Kirin Pharmaceuticals; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Maruho (Inst); Merus (Inst); MSD (Inst); Rakuten Medical Japan (Inst)
 
Shigenori Kadowaki
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Shingo Tamura
Speakers' Bureau - Lilly; MSD; Ono Pharmaceutical
 
Yasuyuki Kajimoto
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Ono Pharmaceutical
 
Ken-ichi Ito
Honoraria - Lilly; Novartis
Consulting or Advisory Role - Novartis
 
Yasushi Ichikawa
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; TERUMO; TERUMO; Yakult Honsha
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yuriko Takeda
No Relationships to Disclose
 
Iwao Sugitani
Honoraria - Eisai; Lilly Japan; Medtronic; Novartis; Ono Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Ono Pharmaceutical